Clinical Trial

Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Name: Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients — clinical trial record (NCT07455006)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate efficacy and of safety QL0911 in the treatment of thrombocytopenia in pediatric patients with previously treated chronic ITP.

Trial Details

NCT Number	NCT07455006
Lead Sponsor	Qilu Pharmaceutical Co., Ltd.
Conditions	Thrombocytopenia, Immune
Enrollment	60 participants
Start Date	2026-04-20
Primary Completion	2027-12-10 (estimated)
Study Completion	2028-03-10 (estimated)
Updated on ClinicalTrials.gov	2026-03-06